CKD-512 / Chong Kun Dang - LARVOL DELTA

Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Chong Kun Dang Pharmaceutical | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Monotherapy • Solid Tumor

Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: Chong Kun Dang Pharmaceutical

Monotherapy • New P1 trial • Solid Tumor